NO961979L - Estramustin formuleringer med forbedrede farmasöytiske egenskaper - Google Patents

Estramustin formuleringer med forbedrede farmasöytiske egenskaper

Info

Publication number
NO961979L
NO961979L NO961979A NO961979A NO961979L NO 961979 L NO961979 L NO 961979L NO 961979 A NO961979 A NO 961979A NO 961979 A NO961979 A NO 961979A NO 961979 L NO961979 L NO 961979L
Authority
NO
Norway
Prior art keywords
estramustine
pct
date
formulations
pharmaceutical properties
Prior art date
Application number
NO961979A
Other languages
English (en)
Other versions
NO961979D0 (no
NO314438B1 (no
Inventor
Alessandro Martini
Giuseppe Maccari
Lorena Muggetti
Giuseppe Colombo
Giovanni Buzzi
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO961979L publication Critical patent/NO961979L/no
Publication of NO961979D0 publication Critical patent/NO961979D0/no
Publication of NO314438B1 publication Critical patent/NO314438B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19961979A 1994-09-22 1996-05-14 Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav NO314438B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419153A GB9419153D0 (en) 1994-09-22 1994-09-22 Estramustine formulations with improved pharmaceutical properties
PCT/EP1995/003438 WO1996009072A1 (en) 1994-09-22 1995-09-01 Estramustine formulations with improved pharmaceutical properties

Publications (3)

Publication Number Publication Date
NO961979L true NO961979L (no) 1996-05-14
NO961979D0 NO961979D0 (no) 1996-05-14
NO314438B1 NO314438B1 (no) 2003-03-24

Family

ID=10761769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961979A NO314438B1 (no) 1994-09-22 1996-05-14 Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav

Country Status (27)

Country Link
US (1) US5712260A (no)
EP (1) EP0730474B1 (no)
JP (1) JP3568957B2 (no)
KR (1) KR960705587A (no)
CN (1) CN1135719A (no)
AT (1) ATE219378T1 (no)
AU (1) AU698425B2 (no)
CA (1) CA2174968A1 (no)
CZ (1) CZ292125B6 (no)
DE (1) DE69527129T2 (no)
DK (1) DK0730474T3 (no)
ES (1) ES2179115T3 (no)
FI (1) FI962120A7 (no)
GB (1) GB9419153D0 (no)
HU (1) HUT75935A (no)
IL (1) IL115376A (no)
MX (1) MX9601852A (no)
MY (1) MY115689A (no)
NO (1) NO314438B1 (no)
NZ (1) NZ292895A (no)
PL (1) PL183132B1 (no)
PT (1) PT730474E (no)
RU (1) RU2179036C2 (no)
TW (1) TW496739B (no)
UA (1) UA48126C2 (no)
WO (1) WO1996009072A1 (no)
ZA (1) ZA957938B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ITMI20031015A1 (it) * 2003-05-20 2004-11-21 Naxospharma S R L Poli-(amminopirrolcarbossammidi) per uso nella profilassi e nel trattamento delle endoparassitosi animali e loro composizioni con ciclodestrine.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299104A (en) * 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
SE8802402D0 (sv) * 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
GB9005133D0 (en) * 1990-03-07 1990-05-02 Ellis J C Ltd Crop lifting apparatus
FR2667070A1 (fr) * 1990-09-21 1992-03-27 Besins Iscovesco Labo Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques.

Also Published As

Publication number Publication date
FI962120A0 (fi) 1996-05-20
JPH09505832A (ja) 1997-06-10
US5712260A (en) 1998-01-27
TW496739B (en) 2002-08-01
PL314584A1 (en) 1996-09-16
IL115376A0 (en) 1995-12-31
DK0730474T3 (da) 2002-09-23
HUT75935A (en) 1997-05-28
UA48126C2 (uk) 2002-08-15
JP3568957B2 (ja) 2004-09-22
KR960705587A (ko) 1996-11-08
MY115689A (en) 2003-08-30
RU2179036C2 (ru) 2002-02-10
EP0730474A1 (en) 1996-09-11
CZ292125B6 (cs) 2003-08-13
PL183132B1 (pl) 2002-05-31
AU698425B2 (en) 1998-10-29
NZ292895A (en) 1998-04-27
PT730474E (pt) 2002-11-29
AU3519995A (en) 1996-04-09
DE69527129D1 (de) 2002-07-25
ZA957938B (en) 1996-04-18
CA2174968A1 (en) 1996-03-28
HU9601738D0 (en) 1996-08-28
ATE219378T1 (de) 2002-07-15
GB9419153D0 (en) 1994-11-09
FI962120L (fi) 1996-05-20
IL115376A (en) 1999-05-09
EP0730474B1 (en) 2002-06-19
CZ145696A3 (en) 1996-08-14
NO961979D0 (no) 1996-05-14
NO314438B1 (no) 2003-03-24
ES2179115T3 (es) 2003-01-16
WO1996009072A1 (en) 1996-03-28
CN1135719A (zh) 1996-11-13
DE69527129T2 (de) 2003-03-06
MX9601852A (es) 1997-03-29
FI962120A7 (fi) 1996-05-20

Similar Documents

Publication Publication Date Title
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
IL133585A0 (en) Soluble prodrugs of paclitaxel
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
NO961979D0 (no) Estramustin formuleringer med forbedrede farmasöytiske egenskaper
HUT77768A (hu) N-szubsztituált azabicikloheptánszármazékok, eljárás előállításukra és alkalmazásuk
NO950177L (no) Farmakologisk aktive erivater
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
HUP9801985A2 (hu) Cisztinszármazékok alkalmazása restenózis gyógyítására használható gyógyszerkészítmények előállítására
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств
IT1252169B (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione, e procedimento per la preparazione dei suddetti principi attivi
RU98114985A (ru) Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы
RU97113700A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики ожирения
AU4544096A (en) New derivatives of glycylanilides, preparation and therapeutical application